Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4012_Библиотеки_им_академика_М_И_Перельмана
.pdf
Wnt Osteoblast Pathway and Ostoprotegerin
87
REFERENCES
[1] Ross R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med.,
1999; 340: 115-126.
[2] London GM. Arteriosclerosis and arterial calcifications in chronic
kidney insufficiency. Nephrol. Ther., 2005; 1(Suppl 4): S351-S354.
[3] Speer MY., Yang HY., Brabb T., Leaf E., Look A., Lin WL., Frutkin
A., Dichek D., Giachelli CM. Smooth muscle cells give rise to
osteochondrogenic precursors and chondrocytes in calcifying arteries.
Circ. Res., 2009; 104: 733-741.
[4] Cannata-Andia JB., Rodriguez-Garcia M., Carrillo-Lopez N.,
Naves-Diaz M., Diaz-Lopez B. Vascular calcifications: pathogenesis,
management, and impact on clinical outcomes. J. Am. Soc. Nephrol.,
2006 (12 Suppl 3); 17: S267-S273.
[5] Moe SM., Chen NX. Mechanisms of vascular calcification in chronic
kidney disease. J. Am. Soc. Nephrol., 2008; 19: 213-216.
[6] Giachelli CM. The emerging role of phosphate in vascular calcification.
Kidney Int., 2009; 75: 890-897.
[7] Pateinakis P., Papagianni A., Douma S., Efstratiadis G., Memmos D.
Associations of fetuin-A and osteoprotegerin with arterial stiffness and
early atherosclerosis in chronic hemodialysis patients. BMC Nephrol.,
2013; 14: 122.
[8] Lu KC., Wu CC., Yen JF., Liu WC. Vascular calcification and renal
bone disorders. ScientificWorldJournal, 2014; 2014: 637065.
[9] Katsiki N., Koumaras C., Athyros VG., Karagiannis A. Thinking
beyond traditional cardiovascular risk factors: The role of arterial
stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
[10] Boutouyrie P., Fliser D., Goldsmith D., Covic A., Wiecek A., Ortiz A.,
Martinez-Castelao A., Lindholm B., Massy ZA., Suleymanlar G., Sicari
R., Gargani L., Parati G., Mallamaci F., Zoccali C., London GM.
Assessment of arterial stiffness for clinical and epidemiological studies:
methodological considerations for validation and entry into the
European Renal and Cardiovascular Medicine registry. Nephrol. Dial.
Transplant., 2014; 29: 232-239.
[11] Modder UI., Hoey KA., Amin S., McCready LK., Achenbach SJ., Riggs
BL., Melton LJ. 3rd, Khosla S. Relation of age, gender, and bone mass
to circulating sclerostin levels in women and men. J. Bone Miner. Res.,
2011; 26: 373-379.
https://t.me/med1917
Eirini Stavrinou, Charalambos Koumaras and Aikaterini Papagianni
88
[12] Thompson B., Towler DA. Arterial calcification and bone physiology:
role of the bone-vascular axis. Nat. Rev. Endocrinol., 2012; 8: 529-543.
[13] Evenepoel P., D'Haese P., Brandenburg V. Sclerostin and DKK1: new
players in renal bone and vascular disease. Kidney Int., 2015; 88: 235-
240.
[14] Naves M., Rodriguez-Garcia M., Diaz-Lopez JB., Gomez-Alonso C.,
Cannata-Andia JB. Progression of vascular calcifications is associated
with greater bone loss and increased bone fractures. Osteoporos. Int.,
2008; 19:1161-1166.
[15] Giallauria F., Ling SM., Schreiber C., Maggio M., Shetty V., Muller D.,
Vigorito C., Ferrucci L., Najjar SS. Arterial stiffness and bone
demineralization: the Baltimore longitudinal study of aging. Am. J.
Hypertens., 2011; 24: 970-975.
[16] Rodriguez-Garcia M., Gomez-Alonso C., Naves-Diaz M., Diaz-Lopez
JB., Diaz-Corte C., Cannata-Andia JB.; Asturias Study Group. Vascular
calcifications, vertebral fractures and mortality in haemodialysis
patients. Nephrol. Dial. Transplant., 2009; 24: 239-246.
[17] Roman-Garcia P., Carrillo-Lopez N., Fernandez-Martin JL., Naves-Diaz
M., Ruiz-Torres MP., Cannata-Andia JB. High phosphorus diet induces
vascular calcification, a related decrease in bone mass and changes in
the aortic gene expression. Bone, 2010; 46: 121-128.
[18] Baron R., Kneissel M. WNT signaling in bone homeostasis and disease:
from human mutations to treatments. Nat. Med. 2013; 19: 179-192.
[19] Ryan ZC., Ketha H., McNulty MS., McGee-Lawrence M., Craig TA.,
Grande JP., Westendorf JJ., Singh RJ., Kumar R. Sclerostin alters serum
vitamin D metabolite and fibroblast growth factor 23 concentrations and
the urinary excretion of calcium. Proc. Natl Acad. Sci. U S A., 2013;
110: 6199-6204.
[20] Kramer I., Loots GG., Studer A., Keller H., Kneissel M. Parathyroid
hormone (PTH)-induced bone gain is blunted in SOST overexpressing
and deficient mice. J. Bone Miner. Res., 2010; 25: 178-189.
[21] Fujita K., Roforth MM., Demaray S., McGregor U., Kirmani S.,
McCready LK., Peterson JM., Drake MT., Monroe DG., Khosla S.
Effects of estrogen on bone mRNA levels of sclerostin and other genes
relevant to bone metabolism in postmenopausal women. J. Clin.
Endocrinol. Metab., 2014; 99: E81-E88.
[22] Cejka D., Jager-Lansky A., Kieweg H., Weber M., Bieglmayer C.,
Haider DG., Diarra D., Patsch JM., Kainberger F., Bohle B.,
Haas M. Sclerostin serum levels correlate positively with bone mineral
https://t.me/med1917
Wnt Osteoblast Pathway and Ostoprotegerin
89
density and microarchitecture in haemodialysis patients. Nephrol. Dial.
Transplant. 2012; 27: 226-230.
[23] Ke HZ., Richards WG., Li X., Ominsky MS. Sclerostin and Dickkopf-1
as therapeutic targets in bone diseases. Endocr. Rev., 2012; 33: 747-783.
[24] Koos R., Brandenburg V., Mahnken AH., Schneider R., Dohmen G.,
Autschbach R., Marx N., Kramann R. Sclerostin as a potential novel
biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J.
Heart Valve Dis., 2013; 22: 317-325.
[25] Pelletier S., Dubourg L., Carlier MC., Hadj-Aissa A., Fouque D. The
relation between renal function and serum sclerostin in adult patients
with CKD. Clin. J. Am. Soc. Nephrol., 2013; 8: 819-823.
[26] Bonani M., Rodriguez D., Fehr T., Mohebbi N., Brockmann J., Blum
M., Graf N., Frey D., Wüthrich RP. Sclerostin blood levels before and
after kidney transplantation. Kidney Blood Press. Res., 2014; 39: 230-
239.
[27] Cejka D., Marculescu R., Kozakowski N., Plischke M., Reiter T., Gessl
A., Haas M. Renal elimination of sclerostin increases with declining
kidney function. J. Clin. Endocrinol. Metab., 2014; 99: 248-255.
[28] Roforth MM., Fujita K., McGregor UI., Kirmani S., McCready LK.,
Peterson JM., Drake MT., Monroe DG., Khosla S. Effects of age on
bone mRNA levels of sclerostin and other genes relevant to bone
metabolism in humans. Bone 2014; 59: 1-6.
[29] Hampson G., Edwards S., Conroy S., Blake GM., Fogelman I., Frost
ML. The relationship between inhibitors of the Wnt signalling pathway
(Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular
calcification and arterial stiffness in post-menopausal women. Bone,
2013; 56: 42-47.
[30] Paccou J., Mentaverri R., Renard C., Liabeuf S., Fardellone P., Massy
ZA., Brazier M., Kamel S. The relationships between serum sclerostin,
bone mineral density, and vascular calcification in rheumatoid arthritis.
J. Clin. Endocrinol. Metab., 2014; 99: 4740-4748.
[31] Claes KJ., Viaene L., Heye S., Meijers B,. d'Haese P., Evenepoel P.
Sclerostin: Another vascular calcification inhibitor? J. Clin. Endocrinol.
Metab., 2013; 98: 3221-3228.
[32] Brandenburg VM., Kramann R., Koos R., Kruger T., Schurgers L.,
Muhlenbruch G., Hübner S., Gladziwa U., Drechsler C., Ketteler M.
Relationship between sclerostin and cardiovascular calcification in
hemodialysis patients: a cross-sectional study. BMC Nephrol., 2013; 14:
219.
https://t.me/med1917
Eirini Stavrinou, Charalambos Koumaras and Aikaterini Papagianni
90
[33] Zhu D., Mackenzie NC., Millan JL., Farquharson C., MacRae VE. The
appearance and modulation of osteocyte marker expression during
calcification of vascular smooth muscle cells. PLoS One, 2011; 6:
e19595.
[34] Kirkpantur A., Balci M., Turkvatan A., Afsar B. Independent
association between serum sclerostin levels and carotid artery
atherosclerosis in prevalent haemodialysis patients. Clin. Kidney J.,
2015; 8: 737-743.
[35] Qureshi AR., Olauson H., Witasp A., Haarhaus M., Brandenburg V.,
Wernerson A., Lindholm B., Söderberg M., Wennberg L., Nordfors L.,
Ripsweden J., Barany P., Stenvinkel P. Increased circulating sclerostin
levels in end-stage renal disease predict biopsy-verified vascular medial
calcification and coronary artery calcification. Kidney Int., 2015; 88:
1356-1364.
[36] Thambiah S., Roplekar R., Manghat P., Fogelman I., Fraser WD.,
Goldsmith D., Hampson G. Circulating sclerostin and Dickkopf-1
(DKK1) in predialysis chronic kidney disease (CKD): relationship with
bone density and arterial stiffness. Calcif. Tissue Int., 2012; 90: 473-
480.
[37] Hsu BG., Liou HH., Lee CJ., Chen YC., Ho GJ., Lee MC. Serum
sclerostin as an independent marker of peripheral arterial stiffness
in renal transplantation recipients: a cross-sectional study. Medicine
(Baltimore), 2016; 95: e3300.
[38] Towler DA. Inorganic pyrophosphate: a paracrine regulator of vascular
calcification and smooth muscle phenotype. Arterioscler. Thromb. Vasc.
Biol., 2005; 25: 651-654.
[39] Kanbay M., Siriopol D., Saglam M., Kurt YG., Gok M., Cetinkaya H.,
Karaman M., Unal HU., Oguz Y., Sari S., Eyileten T., Goldsmith D.,
Vural A., Veisa G., Covic A., Yilmaz MI. Serum sclerostin and adverse
outcomes in nondialyzed chronic kidney disease patients. J. Clin.
Endocrinol. Metab., 2014; 99: E1854-E1861.
[40] Goncalves FL., Elias RM., dos Reis LM., Graciolli FG., Zampieri FG.,
Oliveira RB., Jorgetti V., Moysés RM. Serum sclerostin is an
independent predictor of mortality in hemodialysis patients. BMC
Nephrol., 2014; 15: 190.
[41] Viaene L., Behets GJ., Claes K., Meijers B., Blocki F., Brandenburg
V., Evenepoel P., D'Haese PC. Sclerostin: another bone-related
protein related to all-cause mortality in haemodialysis? Nephrol. Dial.
Transplant., 2013; 28: 3024-3030.
https://t.me/med1917
Wnt Osteoblast Pathway and Ostoprotegerin
91
[42] Drechsler C., Evenepoel P., Vervloet MG., Wanner C., Ketteler M.,
Marx N., Floege J., Dekker FW., Brandenburg VM; NECOSAD Study
Group. High levels of circulating sclerostin are associated with better
cardiovascular survival in incident dialysis patients: results from the
NECOSAD study. Nephrol. Dial. Transplant., 2015; 30: 288-293.
[43] Delanaye P., Krzesinski JM., Warling X., Moonen M., Smelten N.,
Medart L., Bruyère O., Reginster JY., Pottel H., Cavalier E. Clinical
and biological determinants of sclerostin plasma concentration in
hemodialysis patients. Nephron Clin. Pract., 2014; 128: 127-134.
[44] Szulc P., Schoppet M., Rachner TD., Chapurlat R., Hofbauer
LC. Severe abdominal aortic calcification in older men is negatively
associated with DKK1 serum levels: the STRAMBO study. J. Clin.
Endocrinol. Metab., 2014; 99: 617-624.
[45] Register TC., Hruska KA., Divers J, Bowden DW., Palmer ND., Carr
JJ., Wagenknecht LE., Hightower RC., Xu J., Smith SC., Dietzen
DJ., Langefeld CD., Freedman BI. Plasma Dickkopf1 (DKK1)
concentrations negatively associate with atherosclerotic calcified plaque
in African-Americans with type 2 diabetes. J. Clin. Endocrinol. Metab.,
2013; 98: E60-E65.
[46] Kim KI., Park KU., Chun EJ., Choi SI., Cho YS., Youn TJ., Cho GY.,
Chae IH., Song J., Choi DJ., Kim CH. A novel biomarker of coronary
atherosclerosis: serum DKK1 concentration correlates with coronary
artery calcification and atherosclerotic plaques. J. Korean Med. Sci.,
2011; 26: 1178-1184.
[47] Motovska Z., Vichova T., Doktorova M., Labos M., Maly M.,
Widimsky P. Serum Dickkopf-1 signaling and calcium deposition in
aortic valve are significantly related to the presence of concomitant
coronary atherosclerosis in patients with symptomatic calcified aortic
stenosis. J. Transl. Med., 2015; 13: 63.
[48] Askevold ET., Gullestad L., Aakhus S., Ranheim T., Tønnessen T.,
Solberg OG., Aukrust P., Ueland T. Secreted Wnt modulators in
symptomatic aortic stenosis. J. Am. Heart Assoc., 2012; 1: e002261.
[49] Schoppet M., Preissner KT., Hofbauer LC. RANK ligand and
osteoprotegerin: paracrine regulators of bone metabolism and vascular
function. Arterioscler. Thromb. Vasc. Biol., 2002; 22: 549-553.
[50] Baud'huin M., Lamoureux F., Duplomb L., Redini F., Heymann D.
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology
and vascular diseases. Cell. Mole. Life Sci., 2007; 64: 2334-2350.
https://t.me/med1917
Eirini Stavrinou, Charalambos Koumaras and Aikaterini Papagianni
92
[51] Emery JG., McDonnell P., Burke MB., Deen KC., Lyn S., Silverman C.,
Dul E., Appelbaum ER., Eichman C., DiPrinzio R., Dodds RA., James
IE., Rosenberg M., Lee JC., Young PR. Osteoprotegerin is a receptor for
the cytotoxic ligand TRAIL. J. Biol. Chem., 1998; 273: 14363–14367.
[52] Vattikuti R., Towler DA. Osteogenic regulation of vascular
calcification: an early perspective. Am. J. Physiol Endocrinol. Metab.,
2004; 286: E686–E696.
[53] Collin-Osdoby P. Regulation of vascular calcification by osteoclast
regulatory factors RANKL and osteoprotegerin. Circ. Res. 2004; 95:
1046–1057.
[54] Spartalis M., Papagianni A. Receptor activator of nuclear factor kappaB
ligand/osteoprotegerin axis and vascular calcifications in patients with
chronic kidney disease. World J. Nephrol., 2016; 5: 1-5.
[55] Simonet WS., Lacey DL., Dunstan CR., Kelley M., Chang MS., Lüthy
R., Nguyen HQ., Wooden S., Bennett L., Boone T., Shimamoto G.,
DeRose M., Elliott R., Colombero A., Tan HL., Trail G., Sullivan J.,
Davy E., Bucay N., Renshaw-Gegg L., Hughes TM., Hill D., Pattison
W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle
WJ. Osteoprotegerin: a novel secreted protein involved in the regulation
of bone density. Cell, 1997; 89: 309-319.
[56] Bucay N., Sarosi I., Dunstan CR., Morony S., Tarpley J., Capparelli C.,
Scully S., Tan HL., Xu W., Lacey DL., Boyle WJ., Simonet WS.
Osteoprotegerin deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev., 1998; 12: 1260-1268.
[57] Price PA., June HH., Buckley JR., Williamson MK. Osteoprotegerin
inhibits artery calcification induced by warfarin and by vitamin D.
Arterioscler. Thromb. Vasc. Biol., 2001; 21: 1610-1616.
[58] Haufbauer L., Schoppet M. Clinical implications of the osteoprotegerin/
RANKL/RANK system for bone and vascular diseases. JAMA., 2004;
292: 490–495.
[59] Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr
A., Santer P., Smolen J., Poewe W., Willeit J. Osteoprotegerin is a
risk factor for progressive atherosclerosis and cardiovascular disease.
Circulation, 2004; 109: 2175–2180.
[60] Wang JH., Lee CJ., Chen ML., Yang CF., Chen YC., Hsu BG.
Association of serum osteoprotegerin levels with carotid-femoral pulse
wave velocity in hypertensive patients. J Clin Hypertens (Greenwich),
2014; 16: 301-308.
https://t.me/med1917
Wnt Osteoblast Pathway and Ostoprotegerin
93
[61] Gordin D., Soro-Paavonen A., Thomas MC., Harjutsalo V., Saraheimo
M., Bjerre M., Forsblom C., Flyvbjerg A., Groop PH; FinnDiane Study
Group. Osteoprotegerin is an independent predictor of vascular events in
Finnish adults with type 1 diabetes. Diabetes Care, 2013; 36: 1827-
1833.
[62] Bargnoux AS., Dupuy AM., Garrigue V., Deleuze S., Cristol JP.,
Mourad G. Renal transplantation decreases osteoprotegerin levels.
Transplant. Proc., 2006; 38: 2317–2318.
[63] Morena M., Dupuy AM., Jaussent I., Vernhet H., Gahide G., Klouche
K., Bargnoux AS., Delcourt C., Canaud B., Cristol JP. A cut-off value
of plasma osteoprotegerin level may predict the presence of coronary
artery calcifications in chronic kidney disease patients. Nephrol. Dial.
Transplant., 2009; 24: 3389-3397.
[64] Mesquita M., Demulder A., Wolff F., Mélot C., Damry N., Dratwa M.,
Bergmann P. Osteoprotegerin and progression of coronary and aortic
calcifications in chronic kidney disease. Transplant. Proc., 2010; 42:
3444-3449.
[65] Morena M., Jaussent I., Halkovich A., Dupuy AM., Bargnoux AS.,
Chenine L., Leray-Moragues H., Klouche K., Vernhet H., Canaud B.,
Cristol JP. Bone biomarkers help grading severity of coronary
calcifications in non dialysis chronic kidney disease patients. PLoS One,
2012; 7: e36175.
[66] Cianciolo G., La Manna G., Donati G., Persici E., Dormi A.,
Cappuccilli ML., Corsini S., Fattori R., Russo V., Nastasi V., Colì L.,
Wratten M., Stefoni S. Coronary calcifications in end-stage renal
disease patients: a new link between osteoprotegerin, diabetes and body
mass index? Blood Purif., 2010; 29: 13-22.
[67] Nitta K., Akiba T., Uchida K., Otsubo S., Takei T., Yumura W., Kabaya
T., Nihei H. Serum osteoprotegerin levels and the extent of vascular
calcification in haemodialysis patients. Nephrol. Dial. Transplant.,
2004; 19: 1886-1889.
[68] Nitta K., Akiba T., Uchida K., Kawashima A., Yumura W., Kabaya T.,
Nihei H. The progression of vascular calcification and serum
osteoprotegerin levels in patients on long-term hemodialysis. Am. J.
Kidney Dis., 2003; 42: 303–309.
[69] Bargnoux AS., Dupuy AM., Garrigue V., Jaussent I., Gahide G., Badiou
S., Szwarc I., Deleuze S., Vernhet H., Cristol JP., Mourad G. Evolution
of coronary artery calcifications following kidney transplantation:
https://t.me/med1917
Eirini Stavrinou, Charalambos Koumaras and Aikaterini Papagianni
94
relationship with osteoprotegerin levels. Am. J. Transplant., 2009; 9:
2571-2579.
[70] Meneghini M., Regalia A., Alfieri C., Barretta F., Croci D., Gandolfo
MT., Vettoretti S., Rastaldi MP., Messa P. Calcium and osteoprotegerin
levels predict the progression of the abdominal aortic calcifications after
kidney transplantation. Transplantation, 2013; 96: 42-48.
[71] Scialla JJ., Leonard MB., Townsend RR., Appel L., Wolf M., Budoff
MJ, Chen J., Lustigova E., Gadegbeku CA., Glenn M., Hanish A., Raj
D., Rosas SE., Seliger SL., Weir MR., Parekh RS; CRIC Study Group.
Correlates of osteoprotegerin and association with aortic pulse wave
velocity in patients with chronic kidney disease. Clin. J. Am. Soc.
Nephrol., 2011; 6: 2612-2619.
[72] Schlieper G., Brandenburg V., Djuric Z., Damjanovic T., Markovic N.,
Westenfeld R., Dimkovic N., Ketteler M., Floege J. [Is there a
correlation between C-reactive protein and calcification inhibitors with
cardiovascular parameters and risk factors in hemodialysis patients?].
Dtsch. Med. Wochenschr., 2007; 132: 1820-1824.
[73] Shroff RC., Shah V., Hiorns MP., Schoppet M., Hofbauer LC., Hawa
G., Schurgers LJ., Singhal A., Merryweather I., Brogan P., Shanahan C.,
Deanfield J., Rees L. The circulating calcification inhibitors, fetuin-A
and osteoprotegerin, but not matrix Gla protein, are associated with
vascular stiffness and calcification in children on dialysis. Nephrol.
Dial. Transplant.. 2008; 23: 3263-3271.
[74] Speer G., Fekete BC., El Hadj Othmane T., Szabo T., Egresits J., Fodor
E., Kiss I., Logan AG., Nemcsik J., Szabó A., Németh ZK., Szathmári
M., Tislér A. Serum osteoprotegerin level, carotid-femoral pulse wave
velocity and cardiovascular survival in haemodialysis patients. Nephrol.
Dial. Transplant., 2008; 23: 3256-3262.
[75] Nakashima A,. Carrero JJ., Qureshi AR., Hirai T., Takasugi N., Ueno
T., Taniguchi Y., Lindholm B., Yorioka N. Plasma osteoprotegerin,
arterial stiffness, and mortality in normoalbuminemic Japanese
hemodialysis patients. Osteoporos. Int., 2011; 22: 1695-1701.
[76] Lee JE., Kim HJ., Moon SJ., Nam JS., Kim JK., Kim SK., Yun GY., Ha
SK., Park HC. Serum osteoprotegerin is associated with vascular
stiffness and the onset of new cardiovascular events in hemodialysis
patients. Korean J. Intern. Med., 2013; 28: 668-677.
[77] Nascimento MM., Hayashi SY., Riella MC., Lindholm B. Elevated
levels of plasma osteoprotegerin are associated with all-cause mortality
https://t.me/med1917
Wnt Osteoblast Pathway and Ostoprotegerin
95
risk and atherosclerosis in patients with stages 3 to 5 chronic kidney
disease. Braz. J. Med. Biol. Res., 2014; 47: 995-1002.
[78] Morena M., Terrier N., Jaussent I., Leray-Moragues H., Chalabi L.,
Rivory JP., Maurice F., Delcourt C., Cristol JP, Canaud B., Dupuy AM.
Plasma osteoprotegerin is associated with mortality in hemodialysis
patients. J. Am. Soc. Nephrol., 2006; 17: 262-270.
[79] Hjelmesaeth J., Ueland T., Flyvbjerg A., Bollerslev J., Leivestad T.,
Jenssen T., Hansen TK., Thiel S., Sagedal S., Røislien J., Hartmann A.
Early posttransplant serum osteoprotegerin levels predict long-term (8-
year) patient survival and cardiovascular death in renal transplant
patients. J. Am. Soc. Nephrol., 2006; 17: 1746–1754.
[80] Schoppet M., Kavurma MM., Hofbauer LC., Shanahan CM.
Crystallizing nanoparticles derived from vascular smooth muscle cells
contain the calcification inhibitor osteoprotegerin. Biochem. Biophys.
Res. Commun., 2011; 407:103–107.
[81] Evrard S., Delanaye P., Kamel S., Cristol JP., Cavalier E; SFBC/SN
joined working group on vascular calcifications. Vascular calcification:
from pathophysiology to biomarkers. Clin. Chim. Acta. 2015; 438: 401-
414.
[82] Morena M., Jaussent I., Dupuy AM., Bargnoux AS., Kuster N., Chenine
L., Leray-Moragues H., Klouche K., Vernhet H., Canaud B., Cristol JP.
Osteoprotegerin and sclerostin in chronic kidney disease prior to
dialysis: potential partners in vascular calcifications. Nephrol. Dial.
Transplant., 2015; 30: 1345-1356.
[83] Cejka D., Herberth J., Branscum AJ., Fardo DW., Monier-Faugere MC.,
Diarra D., Haas M., Malluche HH. Sclerostin and Dickkopf-1 in renal
osteodystrophy. Clin. J. Am. Soc. Nephrol., 2011; 6: 877-882.
[84] Costa AG., Bilezikian JP., Lewiecki EM. The potential use of
antisclerostin therapy in chronic kidney disease-mineral and bone
disorder. Curr. Opin. Nephrol. Hypertens., 2015; 24: 324-329.
[85] Fang Y., Ginsberg C., Seifert M., Agapova O., Sugatani T., Register
TC., Freedman BI., Monier-Faugere MC., Malluche H., Hruska KA.
CKD-induced wingless/integration1 inhibitors and phosphorus cause the
CKD-mineral and bone disorder. J. Am. Soc. Nephrol., 2014; 25: 1760-
1773.
https://t.me/med1917
Eirini Stavrinou, Charalambos Koumaras and Aikaterini Papagianni
96
[86] MacNabb C., Patton D., Hayes JS. Sclerostin antibody therapy for the
treatment of osteoporosis: clinical prospects and challenges. J.
Osteoporos., 2016; 2016: 6217286.
[87] Holmes D. Bone diseases: Dual sclerostin-DKK1 antibody outperforms
monotherapy. Nat. Rev. Endocrinol., 2016; Jun 17: doi: 10.1038/nrendo.
2016.99. [Epub ahead of print].
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана